Introduction:
The biosimilars market in France is experiencing significant growth as demand for cost-effective alternatives to biologic drugs continues to rise. According to industry reports, the biosimilars market in France is projected to reach €2.5 billion by 2026, driven by increasing investments in research and development and favorable government policies promoting biosimilar adoption.
Top 30 Leading Biosimilars Brands in France 2026:
1. Amgen’s Amjevita
2. Pfizer’s Inflectra
3. Novartis’ Erelzi
4. Samsung Bioepis’ Renflexis
5. Mylan’s Fulphila
6. Sandoz’s Hyrimoz
7. Teva’s Truxima
8. Boehringer Ingelheim’s Cyltezo
9. Biogen’s Imraldi
10. Merck’s Ontruzant
11. Celltrion’s Herzuma
12. Amgen’s Mvasi
13. Pfizer’s Nivestym
14. Novartis’ Rixathon
15. Samsung Bioepis’ Ontruzant
16. Mylan’s Semglee
17. Sandoz’s Erelzi
18. Teva’s Lonquex
19. Boehringer Ingelheim’s Idacio
20. Biogen’s Flixabi
21. Merck’s Renflexis
22. Celltrion’s Truxima
23. Amgen’s Kanjinti
24. Pfizer’s Zirabev
25. Novartis’ Hyrimoz
26. Samsung Bioepis’ Hadlima
27. Mylan’s Ogivri
28. Sandoz’s Ziextenzo
29. Teva’s Udenyca
30. Boehringer Ingelheim’s Abrilada
Insights:
The biosimilars market in France is poised for further growth as the country continues to prioritize the adoption of biosimilar drugs to reduce healthcare costs. With an aging population and increasing prevalence of chronic diseases, biosimilars offer a cost-effective solution for patients in need of biologic treatments. By 2026, the biosimilars market in France is expected to capture 30% of the overall biologics market share, indicating a significant shift towards biosimilar adoption in the country. Additionally, the introduction of new biosimilar brands and increasing investments in research and development will continue to drive the growth of the biosimilars market in France in the coming years.
Related Analysis: View Previous Industry Report
